AZA
TEVA icon

Arthur Zaske & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Arthur Zaske & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$400K Hold
21,115
– – 0.44% 37
2017
Q3 		$372K Buy
+21,115
New +$475K 0.39% 37

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Arthur Zaske & Associates's TEVA Position: Q4 2017 in Review

Arthur Zaske & Associates held its Teva Pharmaceuticals (TEVA) position steady in Q4 2017 at 21,115 shares worth $400K. The position accounts for 0.44% of the portfolio, ranked #37.

Arthur Zaske & Associates first reported a position in TEVA in Q3 2017 and has held it in 2 quarters since. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Arthur Zaske & Associates held 21,115 shares of Teva Pharmaceuticals worth $400K as of Q4 2017.
  • Arthur Zaske & Associates left its Teva Pharmaceuticals share count unchanged in Q4 2017.
  • Teva Pharmaceuticals made up 0.44% of Arthur Zaske & Associates's portfolio in Q4 2017, its #37 holding.
  • Arthur Zaske & Associates first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 2 quarters since.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Arthur Zaske & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.